Target intelligence / Profile preview

Group B Streptococcus serotype Ia capsular polysaccharide (GBS Ia CPS)

Target
GBS Ia CPS
Molecular classification
Polysaccharide, Bacterial surface antigen, Carbohydrate
01

Overview

The Group B Streptococcus (GBS) serotype Ia capsular polysaccharide is a complex carbohydrate structure located on the outermost layer of the bacterium Streptococcus agalactiae. It serves as a critical virulence factor by acting as a physical barrier that prevents C3 deposition and subsequent opsonophagocytosis by host immune cells. The biochemical structure of the serotype Ia polysaccharide is characterized by a repeating unit containing glucose, galactose, N-acetylglucosamine, and a terminal alpha-2,3-linked sialic acid residue, which mimics human cell surface glycans to evade immune detection. In clinical medicine, this polysaccharide is a primary target for prophylactic vaccines designed to prevent invasive GBS disease in neonates and pregnant women. Therapeutic strategies focus on conjugate vaccines where the polysaccharide is linked to a carrier protein, such as CRM197, to elicit a robust T-cell dependent immune response and long-lasting antibody production.

Other names
Streptococcus agalactiae serotype Ia capsular polysaccharideGBS Type Ia polysaccharideGroup B Streptococcal capsular polysaccharide IaType Ia CPS
02

Mechanism of action

Induction of serotype-specific opsonophagocytic antibodies (IgG) that promote bacterial killing by neutrophils and macrophages.

03

Biological functions

Bacterial virulenceInhibition of phagocytosisImmune system evasionAlternative complement pathway inhibition
04

Disease associations

Neonatal sepsisMeningitisPneumoniaMaternal infectionSkin and soft tissue infection
05

Safety considerations

Serotype replacementPotential cross-reactivity with host glycansInjection site reactions (vaccine-related)
06

Interacting drugs

GBS6 (Hexavalent Group B Streptococcus conjugate vaccine)

2 more in the full profile.

07

Biomarkers

Anti-CPS Ia IgG concentrationOpsonophagocytic killing assay (OPKA) titers

Beyond the preview

Go deeper on Group B Streptococcus serotype Ia capsular polysaccharide (GBS Ia CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group B Streptococcus serotype Ia capsular polysaccharide (GBS Ia CPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call